Literature DB >> 17396201

Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.

Marcelo Pereira da Rosa1, Gislaine Verginia Baroni, Vera Lúcia Portal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17396201     DOI： 10.1590/s0066-782x2006001800035

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN： 0066-782X            Impact factor:   2.000


× No keyword cloud information.
  2 in total

1.  Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.

Authors:  Won-Kyo Jung; Da-Young Lee; Cheol Park; Yung Hyun Choi; Inhak Choi; Sae-Gwang Park; Su-Kil Seo; Soo-Woong Lee; Sung Su Yea; Soon-Cheol Ahn; Chang-Min Lee; Won Sun Park; Jae-Hong Ko; Il-Whan Choi
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

2.  Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.

Authors:  Kyung-Yeon Park; Euichaul Oh; Mi-Kyoung Kwak; Hyun Sik Jun; Tae-Hwe Heo
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.